GPR35 and atherosclerosis: Given that overactivation of the NLRP3 inflammasome leads to inflammatory diseases such as Alzheimer’s disease, gout, and atherosclerosis (48), KA or other agonists of GPR35 might have potential as new therapeutics for NLRP3-triggered diseases.